Tag Archives: Telotristat etiprate

September, 2016

  • 15 September

    FDA Extends PDUFA Date for Lexicon’s Carcinoid Syndrome Drug

    THE WOODLANDS, Texas, Sept. 14, 2016 /PRNewswire/ — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (“FDA”) will require additional time to complete its review of the New Drug Application (“NDA”) for telotristat etiprate, an oral drug for the treatment of carcinoid syndrome.  In …